| INTRODUC TI ON
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with a 5-fold increased risk of stroke. 1 The introduction of non-vitamin K antagonist oral anticoagulants, direct oral anticoagulants (DOACs), has been a major advance in stroke prevention in patients with AF. Compared with warfarin, DOACs are more convenient to use and demonstrated at least equivalent effectiveness, with less intracranial bleeding, in pivotal clinical trials.
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Edoxaban is an oral, reversible, and direct factor Xa inhibitor [6] [7] [8] that originated in Japan and has a linear and predictable pharmacokinetic profile: 62% oral bioavailability, maximum concentration achieved within 1-2 hours, 9 and 50% excreted by the kidney. 10 It was approved for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) in Japan in 2014. It is also used for two further indications: treatment and prevention of recurrence of venous thromboembolism, and prevention of postoperative venous thromboembolism after lower extremity orthopedic surgery. 11 Edoxaban is the only DOAC approved for these three indications in Japan.
The number of patients with AF in Japan is predicted to surpass 1 million by 2050, 12, 13 and thus the requirement for DOAC therapy to prevent stroke is expected to increase. Because edoxaban is also available as an orally degradable formulation (OD tablet), it can be prescribed for elderly patients with dysphagia and will become a drug of choice, once its safety and effectiveness profiles are fully established. However, no large-scale clinical study of edoxaban in a real-world setting is currently available. Our ongoing study, ETNA-AF-Japan (UMIN000017011), was initiated in the hope of collecting such data for a 2-year follow-up period.
In this article, we describe an interim analysis on data from the 3-month case reports in ETNA-AF-Japan. This interim analysis was conducted to provide healthcare professionals with outcomes of practical use promptly even though the case report collection was not completed, because no other data for large-scale postmarketing surveillance on real-world use of edoxaban are available. A periodic safety report based on the identical interim data set (8377 patients)
has been submitted to Pharmaceuticals and Medical Devices Agency.
| ME THODS
This post-authorization safety and effectiveness study of edoxaban in Japanese patients with NVAF was conducted in accordance with the standards for Good Post-marketing Study Practice provided by the Ministry of Health, Labour, and Welfare in Japan.
| Study design
ETNA-AF-Japan is a real-world, prospective, observational study that aims to collect the baseline characteristics of Japanese patients with NVAF and survey the effectiveness and safety of edoxaban in these patients.
The standard observation period was 2 years and the target patient number was 10 000. The enrollment started on 13 April 2015, and 11 569 patients were enrolled by 30 September 2017.
The observational study was carried out using a central registration system.
| Patient population
Eligible patients were those who fulfilled the following criteria: patients diagnosed with NVAF and intending to receive edoxaban for the first time to prevent ischemic stroke and systemic embolism; patients who started to take edoxaban within the contract period (determined for each participating institution) and within the registration period; patients who could participate for the observation period;
and patients who provided written consent to participate at the time of registration. The data for these survey variables were collected on case report forms after 3, 12, and 24 months of study participation, and stored in an electronic data capture system. In the present analysis, we evaluated the data from the case report forms collected after 3 months of study participation.
| Survey variables

| Study outcomes
The data for the survey variables were expected to provide an Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) 14 with slight modifications (Appendix S1). 
| Data analysis
| Baseline characteristics
The baseline characteristics of the patients are summarized in Table 1 , and the distribution of important factors including age, CLcr, CHADS 2 score, CHA 2 DS 2 -VASc score, and HAS-BLED score are shown in The mean body weight was 60.0 ± 12.6 kg, and 54.6% of patients had body weight ≤60 kg. Regarding types of AF, 46.1% of patients had paroxysmal AF, 38.7% had persistent AF, and 15.1% had permanent AF.
The mean CLcr was 64.0 ± 25.6 mL/min, and patients with CLcr >50 to <80 mL/min were most common at 45.4% ( Figure 1B) . Meanwhile, 4.7% of patients had CLcr <30 mL/min, which was an exclusion criterion for the phase 3 study (ENGAGE AF-TIMI 48 14 ). The mean CHADS 2 score was 2.2 ± 1.3, and the most common score was 2 in 29.8% of patients ( Figure 1C ). Overall, 34.2% of patients had CHADS 2 scores ≤1 ( Figure 1C ), which were outside the inclusion criteria for the ENGAGE AF-TIMI 48. The mean CHA 2 DS 2 -VASc score was 3.5 ± 1.6 and the most common score was 3 ( Figure 1D ). The mean HAS-BLED score was 2.0 ± 1.0 and the most common score was 2 ( Figure 1E ). Among 24.2%
patients treated with other anticoagulants prior to administration of edoxaban, 12.2%, 4.0%, 3.3%, and 3.2%, were treated with warfarin, rivaroxaban, apixaban, and dabigatran, respectively. At the start of edoxaban, antiplatelet agents were used in 12.0% of patients, including aspirin (7.1%) and dual antiplatelet therapy (1.2%). Among the Pglycoprotein (P-gp) inhibitors, quinidine, verapamil, erythromycin, and cyclosporine were used in 5.3% of patients, and other P-gp inhibitors were used in 9.2% of patients. Table 2 summarizes the medical histories and comorbidities.
| Medical history and comorbidities
Medical history of bleeding was found in 5.7% of patients, including intracranial bleeding (2.5%) and gastrointestinal bleeding (1.7%).
Medical history other than bleeding included hypertension (72.4%), dyslipidemia (36.4%), and diabetes mellitus (23.3%). Table 1 summarizes the numbers of patients at each dosage level. As a starting daily dose, 27.0%, 72.3%, and 0.7% of patients were given 60, 30, and 15 mg edoxaban, respectively, as also illustrated in Figure 2A .
| Dosage levels and their adjustment factors
Following the prescribing information, the dosage for individual patients was determined as follows ( Figure 2B ). Patients with body weight >60 kg were generally given 60 mg edoxaban. The dosage level was reduced to 30 mg if patients had body weight ≤60 kg, CLcr ≤50 mL/min, or concomitant medication with P-gp inhibitor, quinidine, verapamil, erythromycin, and/or cyclosporine. Of the total 8157 patients, information on dose-adjusting factors was available for 8027 patients, and the initial dose for these patients was analyzed as shown in Figure 2B . Figure 2C . The remaining 36.6% of patients had none of the three factors. Of these patients, 67.7% were administered 60 mg edoxaban and 32.1% were administered 30 mg. The dose reduction in patients with no dose-adjusting factors was determined by each attending physician based on the clinical status of the individual patient and factors including age (43.6%), CLcr (23.3%), body weight (12.9%), combination use of P-gp inhibitors (7.6%), and others (26.4%). Labile international normalized ratio and alcohol use were not counted; thus, the highest total score was 7.
| Continuation and discontinuation of medication
subarachnoid bleeding). Adverse drug reactions (ADRs) were detected in 5.22% of patients, with serious ADRs in 0.99%.
| D ISCUSS I ON
This is a 3-month interim report on 8157 patients among the 11 569 patients enrolled in ETNA-AF-Japan, an ongoing, largescale, prospective, observational study to evaluate the safety and effectiveness of edoxaban in Japanese patients with NVAF. In the present study, we focused on the baseline characteristics of patients and bleeding AEs, which we believe to be of clinical importance in the early stages of anticoagulant therapy. A more detailed profile of the safety and effectiveness of edoxaban treatment including thromboembolic AEs will be reported after completion of the 1-year follow-up as an interim report and then after completion of the ongoing 2-year observation study as a report of the final results.
The baseline characteristics of these 8157 patients revealed that 52.4% were aged ≥75 years, and 31.4% were aged ≥80 years.
Because AF is estimated to occur in 7%-15% and 2%-3% of people aged ≥80 years in Western countries 15 and in Japan, 12, 13 The mean age and age distribution of the patients in the present study were quite similar to those in the Fushimi registry. 18 The mean CLcr was identical in both studies. The CHADS 2 score and its distribution were also similar in both studies. The mean age of patients in the present study was 74.2 years, the mean CLcr was lower with 64.0 mL/min, and the mean CHADS 2 score was 2.2. The mean CHADS 2 score in the present study was identical to that in the XAPASS with a similar distribution. Thus, the patients in the present study were older with lower renal function and higher risk for stroke than those in the two previous studies.
Based on the above comparisons, the patient population in the present study appears to overlap the populations in the Fushimi registry, XAPASS, and J-dabigatran surveillance, and thus seems to reflect the current general elderly patient population with NVAF.
In the present study, the initial dose of edoxaban was 60 mg in Compared with those appropriately receiving standard doses, patients receiving inappropriately reduced DOAC doses had higher unadjusted rates of thromboembolic events and death. However, after adjustment for baseline characteristics of the patients, the outcomes did not differ significantly, but showed a tendency to favor patients with appropriate doses. 23 In the Fushimi AF registry, 36%-59% of patients receiving reduced doses of DOAC were prescribed a dose inconsistent with the recommended dose (off-label underdose). 24 Using a large US administration database, Yao et al difficult, however, to determine whether the reduced dose was clinically appropriate at this early stage of edoxaban treatment.
We are aware of the importance of this issue, and will continue to carefully observe the clinical outcome of these patients. Upon completion of the ongoing 2-year observation study, we expect to provide more information to help establish a better strategy for the treatment of elderly patients with NVAF.
To date, 90.8% of patients have continued administration of edoxaban for >3 months, a higher rate compared with other studies of longer duration, 21, 26 except for a study by Inoue et al 20 in which the adherence rate for the first 3 months was >90% and comparable to the present study. It will be interesting to see whether this adherence continues for a longer period.
This article describes the results for the 3-month follow-up data and no significant safety concerns were found. The final 2-year follow-up results are awaited.
| Limitations
The present study was an open-label observational study with no positive control. The duration of the study was also very limited.
However, the ongoing 2-year research may add more convincing data and may provide a clearer view regarding the safety and effectiveness profiles of edoxaban in real-world clinical practice as well as hints for better adherence to DOAC therapy.
| CON CLUS IONS
The present study, an interim analysis at 3 months on 8157 patients analyzed in ETNA-AF-Japan, has demonstrated that treatment with edoxaban for 3 months was well tolerated in Japanese patients with NVAF, including those with limited renal function who were excluded 
ACK N OWLED G EM ENTS
The authors express their deepest gratitude to the investigators who conducted this survey and provided valuable data. This study was funded by Daiichi Sankyo Co. Ltd. Writing and editing assistance were provided by ASCA Corporation and funded by Daiichi Sankyo
Co. Ltd.
CO N FLI C T O F I NTE R E S T
TY received consulting and lecture fees from Daiichi Sankyo Co. 
